Comparison of long-term cardiovascular and renal outcomes between percutaneous coronary intervention and coronary artery bypass grafting in multi-vessel disease with chronic kidney disease

Woochan Kwon\textsuperscript{1,}†, Ki Hong Choi\textsuperscript{1,}†, Dong Seop Jeong\textsuperscript{2}, Sang Yoon Lee\textsuperscript{1}, Joo Myung Lee\textsuperscript{1}, Taek Kyu Park\textsuperscript{1}, Jeong Hoon Yang\textsuperscript{1}, Joo-Yong Hahn\textsuperscript{1}, Seung-Hyuk Choi\textsuperscript{1}, Su Ryeun Chung\textsuperscript{2}, Yang Hyun Cho\textsuperscript{2}, Kiick Sung\textsuperscript{2}, Wook Sung Kim\textsuperscript{2}, Hyeon-Cheol Gwon\textsuperscript{1}, Young Tak Lee\textsuperscript{2*} and Young Bin Song\textsuperscript{1*}

\textsuperscript{1}Division of Cardiology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Heart Vascular Stroke Institute, Seoul, South Korea. \textsuperscript{2}Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Heart Vascular Stroke Institute, Seoul, South Korea

Objective: This study aims to analyze cardiac and renal outcomes of chronic kidney disease (CKD) patients with multi-vessel disease who have undergone coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI).

Materials and methods: Chronic kidney disease patients with multi-vessel disease who underwent CABG or PCI were retrospectively selected from our database and divided into the PCI group [further stratified into PCI with complete revascularization (PCI-CR) and PCI with incomplete revascularization (PCI-IR) groups] and the CABG group. The primary endpoint was the composite of all-cause death, myocardial infarction (MI), or stroke at 5 years. The key secondary endpoint was the 5-year rate of the renal composite outcome, defined as >40% glomerular filtration rate decrease, initiation of dialysis, and/or kidney transplant. Outcomes were compared using Cox proportional hazards regression analysis, and the results were further adjusted by multivariable analyses and inverse probability weighting.

Results: Among the study population ($n = 798$), 443 (55.5%) patients received CABG and 355 (44.5%) patients received PCI. Compared with the CABG group,
the PCI group had similar risk of the primary endpoint (CABG vs. PCI, 19.3% vs. 24.0%, HR: 1.28, 95% CI: 0.95–1.73, p = 0.11) and a lower risk of the renal composite outcome (36.6% vs. 31.2%, HR: 0.74, 95% CI: 0.58–0.94, p = 0.03). In addition, PCI-IR was associated with a significantly higher risk of the primary endpoint than CABG (HR: 1.54, 95% CI: 1.11–2.13, p = 0.009) or PCI-CR (HR: 1.78, 95% CI: 1.09–2.89, p = 0.02). However, PCI-CR had a comparable 5-year death, MI, or stroke rate to CABG (HR: 0.86, 95% CI: 0.54–1.38, p = 0.54).

**Conclusion:** Coronary artery bypass grafting showed an incidence of death, MI, or stroke similar to PCI but was associated with a higher risk of renal injury. PCI-CR had a prognosis comparable with that of CABG, while PCI-IR had worse prognosis. If PCI is chosen for revascularization in patients with CKD, achieving CR should be attempted to ensure favorable outcomes.

**Clinical trial registration:** [clinicaltrials.gov], identifier [NCT 03870815].

**KEYWORDS**
coronary artery disease, percutaneous coronary intervention, coronary artery bypass grafting, chronic renal insufficiency, clinical outcomes

---

**Introduction**

Chronic kidney disease (CKD) is an important risk factor for coronary artery disease, associated not only with its development and progression but also with morbidity and mortality thereafter (1). Patients with CKD alone have a higher mortality risk after myocardial infarction (MI) than those with diabetes mellitus or a prior history of MI (2). Several studies have reported that coronary artery bypass grafting (CABG), compared with percutaneous coronary intervention (PCI), is associated with a higher risk of short-term death and stroke but reduced long-term risk of MI or repeat revascularization in patients with CKD (3, 4). Patients with CKD are also at risk for acute kidney injury (AKI), a common complication after CABG or PCI (5), and for progression to end-stage renal disease (6). Although many studies have concluded that PCI preserves renal function better (5, 7), most of these studies have been conducted on a short-term follow-up, and data on other kidney-related outcomes such as initiation of dialysis or kidney transplant are scarce.

Outcomes of PCI can differ according to completeness of revascularization. Previous observational studies have found significant benefit of complete revascularization (CR) compared with incomplete revascularization (IR) (8, 9). Outcomes of PCI with CR can be similar to those of CABG (10). Cardiac and renal outcomes have not been comprehensively compared between PCI and CABG, especially according to completeness of revascularization of PCI. We therefore compared long-term cardiovascular and renal outcomes among patients with CKD and multi-vessel disease who received CABG or PCI based on the data from a comprehensive institutional registry.

**Materials and methods**

**Study population and data collection**

This was a retrospective, single-center, and observational study conducted from January 2008 to December 2015. During this time period, CKD patients with multi-vessel disease (defined as having two or more diseased coronary arteries) who underwent CABG or PCI were recruited. The data were taken from a comprehensive registry of Samsung Medical Center consisting of adult (older than 18 years) patients with ischemic heart disease who underwent CABG or PCI with second-generation drug-eluting stents (clinicaltrials.gov, NCT 03870815). Exclusion criteria for this study were cardiogenic shock, emergent procedure, age over 80 years, being on dialysis before the procedure, and unavailable glomerular filtration rate (GFR) data. Finally, 798 subjects were enrolled and divided into the PCI group (n = 355) and CABG group (n = 443). The PCI group was further stratified into PCI-CR (n = 132) and PCI-IR (n = 223) groups (Figure 1).

Baseline demographic, angiographic, and procedural data, and adverse outcomes during the follow-up period...
were collected prospectively from our registry by research coordinators. Additional information was obtained from medical records and telephone interviews, if necessary. Mortality data for patients lost to follow-up were confirmed from the national death records. All events were adjudicated by a cardiologist who was blinded to the treatment strategy. The study protocol was approved and requirement for informed consent was waived by the Institutional Review Board of Samsung Medical Center. This study was conducted in accordance with the Declaration of Helsinki.

All revascularization procedures are described in detail in Supplementary material.

Definitions and outcomes

Chronic kidney disease was defined as a GFR less than 60 mL/min/1.73 m² as calculated by using the CKD Epidemiology Collaboration equation, both at the baseline and post-procedure stabilization (11). Multi-vessel disease was defined as the presence of luminal stenosis 50% or greater in two or more major epicardial arteries on coronary angiography. In the PCI group, anatomic CR was defined as visually estimated residual stenosis < 30% in vessels with a diameter of 2.25 mm or wider coronary branches with Thrombolysis In Myocardial Infarction grade 3 flow in all arteries at the end of the procedure (12); all other cases were defined as anatomic IR.

The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), a composite of all-cause death, MI, or stroke at 5 years. The key secondary endpoint was the 5-year rate of renal composite outcomes, defined as a GFR decrease of more than 40% of the baseline value, new requirement for dialysis (both emergent and elective), or kidney transplant. Other secondary endpoints included all-cause death, cardiac death, MI, stroke, and repeat revascularization at 5 years. All deaths were considered cardiac-related, unless a definite non-cardiac cause was established. MI was defined as elevated cardiac enzymes (troponin or myocardial band fraction of creatine kinase) greater than the upper reference limit with concomitant ischemic symptoms or electrocardiography findings indicative of ischemia. Periprocedural MI was not included as a clinical event. Stroke was defined as a neurological deficit attributable to an acute focal injury of the central nervous system caused by cerebral infarction or hemorrhage, with the supporting findings on brain imaging. Repeat revascularization was defined as unplanned revascularization for any coronary arteries after the index PCI or CABG procedure.

Statistical analysis

Categorical variables are presented as numbers and relative frequencies (%) and were compared using the chi-square test. Continuous variables are presented as means ± standard deviations or median with interquartile range according to distribution of data as tested by the Kolmogorov–Smirnov test, and were analyzed using Welch’s t-test or Mann–Whitney U test, respectively. The cumulative incidence of primary and secondary endpoints at 5 years were calculated using the Kaplan–Meier method and were compared between groups using the log-rank test. Cardiovascular and renal outcomes were compared using Cox proportional hazard regression models.
Comparison of outcomes between the coronary artery bypass grafting and percutaneous coronary intervention groups

The median follow-up duration of the cohort was 2.77 (interquartile range 0.97–5.27) years. Compared with CABG, PCI had a similar risk of MACCE at 5 years (PCI vs. CABG, 24.0% vs. 19.3%, HR 1.28, 95% CI 0.95–1.73, p = 0.11) (Figure 2A and Table 2), although the risk was significantly higher in the PCI group after IPW adjustment. The risk of repeat revascularization was significantly higher in the PCI group than in the CABG group (PCI vs. CABG, 11.1% vs. 2.2%, HR 5.35, 95% CI 2.58–11.10, p < 0.001). By contrast, patients treated with PCI had a significantly lower risk of stroke (PCI vs. CABG, 4.4% vs. 8.8%, HR 0.51, 95% CI 0.28–0.93, p = 0.04) and renal composite outcome (PCI vs. CABG, 31.2% vs. 36.6%, HR 0.74, 95% CI 0.58–0.94, p = 0.03) than those treated with CABG (Figure 2B and Table 2). The results were mostly consistent after adjustment for baseline differences in multivariable and IPW analyses.

A landmark analysis was performed to assess the risk of PCI or CABG on both short-term and long-term follow-ups. A similar incidence of MACCE of the PCI and CABG groups was shown both before and after 1-year point, although CABG showed a slight trend toward a lower incidence of MACCE compared with the PCI group (Supplementary Figure 1).

Meanwhile, compared with CABG, PCI had beneficial effects on the risk of the renal composite outcome within 30 days of the index procedure, with continued divergence of the curves throughout the study period (Figure 3).

Comparison of outcomes among the percutaneous coronary intervention with complete revascularization, percutaneous coronary intervention with incomplete revascularization, and coronary artery bypass grafting groups

There was a significant difference in the incidence of 5-year MACCE between patients who were treated with PCI-IR and those treated with CABG (PCI-IR vs. CABG, 28.3% vs. 19.3%, HR 1.54, 95% CI 1.11–2.13, p = 0.009) or PCI-CR (PCI-IR vs. PCI-CR, 28.3% vs. 16.7%, HR 1.78, 95% CI 1.09–2.89, p = 0.02), but there was no significant difference in the incidence of 5-year MACCE between patients treated with PCI-CR and those treated with CABG (PCI-CR vs. CABG, 16.7% vs. 19.3%, HR 0.86, 95% CI 0.54–1.38, p = 0.54) (Figure 4 and Tables 3, 4).

Compared with patients treated with CABG, those treated with PCI-CR showed comparable cardiac death, MI, and stroke rates. However, there was a significantly higher incidence of repeat...
revascularization in the PCI-CR group in addition to the PCI-IR group than in the CABG group (Tables 3, 4 and Supplementary Figure 2). Meanwhile, there were fewer adverse renal outcomes in the PCI-CR group than in the CABG group (renal composite outcome in the PCI-CR vs. CABG groups, 26.9% vs. 36.6%, HR 0.64, 95% CI 0.44–0.92, p = 0.02), while the incidence of the renal composite outcome in the PCI-IR group was not significantly different from that of the CABG or PCI-CR groups (Tables 3, 4).

**Discussion**

We evaluated the impact of different revascularization methods on cardiovascular and renal outcomes in patients with CKD. We also assessed whether outcomes of PCI depend on the completeness of revascularization. Our major findings are as follows. First, PCI is associated with a risk of MACCE similar to CABG but protects kidney function better than CABG in patients with CKD. Second, PCI-CR has a risk of MACCE at 5 years comparable to CABG. Third, PCI-IR is associated with a higher risk of MACCE than both PCI-CR and CABG.

**CARDIOVASCULAR ADVERSE EVENTS**

Several studies have investigated cardiovascular outcomes after PCI or CABG in patients with CKD. While CABG was reported to be associated with a higher risk of short-term

| TABLE 1 Comparison of baseline characteristics according to the revascularization method. |
|-----------------------------------------------|------------------|------------------|------------------|
| Variables                                   | CABG (N = 443)   | PCI (N = 355)    | P-value          |
| Demographics                                |                  |                  |                  |
| Age (years)                                 | 70.0 [64.0, 74.0] | 71.0 [65.0, 75.0] | 0.005            |
| Male                                        | 303 (68.4%)      | 249 (70.1%)      | 0.60             |
| Body mass index (kg/m²)                     | 24.6 [22.7, 26.8] | 24.6 [22.8, 26.5] | 0.92             |
| Cardiovascular risk factors                 |                  |                  |                  |
| Hypertension                                | 352 (79.5%)      | 280 (78.9%)      | 0.84             |
| Diabetes mellitus                           | 293 (66.1%)      | 258 (72.7%)      | 0.05             |
| History of myocardial infarction            | 43 (9.7%)        | 46 (13.0%)       | 0.15             |
| History of PCI                              | 83 (18.7%)       | 88 (24.8%)       | 0.04             |
| History of CABG                             | 7 (1.6%)         | 31 (8.7%)        | <0.001           |
| History of stroke                           | 83 (18.7%)       | 41 (11.5%)       | 0.01             |
| Initial presentation                        |                  |                  |                  |
| Diagnosis at presentation                   |                  |                  |                  |
| Acute myocardial infarction                 | 62 (14.0%)       | 60 (16.9%)       | 0.26             |
| Stable angina                               | 209 (47.2%)      | 225 (63.4%)      | <0.001           |
| Unstable angina                             | 172 (38.8%)      | 70 (19.7%)       | <0.001           |
| Pre-procedure LVEF (%)                      | 56.4 [42.5, 64.0] | 59.0 [46.0, 65.0] | 0.03             |
| LVEF < 40% at baseline                      | 105 (23.7%)      | 125 (35.2%)      | <0.001           |
| Creatinine (mg/dL)                          | 1.4 [1.2, 1.7]   | 1.4 [1.2, 1.7]   | 0.99             |
| Glomerular filtration rate (mL/min/1.73 m²) | 49.5 [38.8, 55.9] | 50.8 [38.0, 55.7] | 0.86             |
| Hemoglobin (mg/dL)                          | 11.9 [10.5, 13.3] | 12.0 [11.0, 14.0] | 0.001            |
| C-reactive protein (mg/L)                   | 0.2 [0.1, 0.8]   | 0.2 [0.1, 0.5]   | 0.01             |
| Coronary anatomy                            |                  |                  |                  |
| Left main involvement                       | 79 (17.8%)       | 27 (7.6%)        | <0.001           |
| Number of involved vessels                  |                  |                  | <0.001           |
| 2-vessel disease                            | 93 (21.0%)       | 186 (52.4%)      | <0.001           |
| 3-vessel disease                            | 350 (79.0%)      | 169 (47.6%)      | <0.001           |
| Medication at discharge                     |                  |                  |                  |
| Aspirin                                     | 430 (97.1%)      | 353 (99.4%)      | 0.03             |
| P2Y12 inhibitor                             | 322 (72.7%)      | 353 (99.4%)      | <0.001           |
| Beta blocker                                | 372 (84.0%)      | 220 (62.0%)      | <0.001           |
| RAS blocker                                 | 121 (27.3%)      | 264 (74.4%)      | <0.001           |
| Statin                                      | 317 (71.6%)      | 330 (83.0%)      | <0.001           |

Values are means ± standard deviations (or median [1st interquartile, 3rd interquartile]) or numbers (%). CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; LVEF, left ventricular ejection fraction; RAS, renin-angiotensin system.
Comparison of 5-year MACCE between CABG and PCI. Kaplan–Meier curve comparing (A) MACCE and (B) stroke at the 5-year point between the CABG and PCI groups. CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; MACCE, major adverse cardiac and cerebrovascular events.

TABLE 2 Comparison of clinical outcomes at 5 years in the CABG and PCI groups.

| Variables                  | CABG (N = 443) | PCI (N = 355) | Univariable analysis | Multivariable analysis* | IPW analysis |
|----------------------------|----------------|---------------|----------------------|-------------------------|--------------|
|                            | HR (95% CI)    | P-value       | HR (95% CI)          | P-value                 | HR (95% CI) |
| MACCE                      | 1.28 (0.95–1.73) | 0.11          | 1.33 (0.96–1.85)     | 0.09                    | 1.46 (1.05–2.02) |
| Death                      | 1.59 (1.13–2.26) | 0.01          | 1.61 (1.10–2.35)     | 0.01                    | 1.63 (1.13–2.35) |
| Cardiac death              | 1.49 (0.96–2.33) | 0.08          | 1.47 (0.90–2.38)     | 0.12                    | 1.52 (0.95–2.42) |
| Acute myocardial infarction| 3.24 (1.02–10.33) | 0.05          | 3.92 (1.14–13.45)    | 0.03                    | 2.99 (0.92–9.75) |
| Stroke                     | 0.51 (0.28–0.93) | 0.04          | 0.58 (0.31–1.07)     | 0.08                    | 0.51 (0.19–0.97) |
| Repeat revascularization   | 5.35 (2.58–11.10) | <0.001        | 5.99 (2.78–12.88)    | <0.001                  | 5.10 (2.42–10.8) |
| Renal composite outcome†   | 0.74 (0.58–0.94) | 0.03          | 0.71 (0.54–0.93)     | 0.01                    | 0.77 (0.59–0.99) |

*Multivariable adjusted analysis was performed with the variables of age over 70 years, sex, acute myocardial infarction at presentation, hypertension, diabetes mellitus, left ventricular ejection fraction under 40%, history of stroke, left main coronary artery involvement, and three-vessel disease.
†Renal composite outcome was defined as a decrease in the GFR of more than 40%, initiation of dialysis, or kidney transplant during the follow-up.

All analyses were performed with the CABG group as the reference.

CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; IPW, inverse probability weighting; HR, hazard ratio; CI, confidence interval; MACCE, major adverse cardiac and cerebrovascular events.

mortality and stroke, MI and repeat revascularization were less frequent than in those who had undergone PCI in the long-term follow-up (3, 4, 13, 14). The majority of these studies designated MACCE as the primary outcome and concluded CABG is associated with fewer adverse events in patients with CKD than in PCI (14, 15). However, some studies have published contrary findings (16, 17), most likely due to differences in the stent type and definitions of the primary outcome. Therefore, we sought to better clarify the risk of PCI in the current-generation drug-eluting stenting and compare it with that of CABG. We found a similar incidence of the composite of all-cause death, MI, or stroke at 5 years in the PCI groups, even after thorough adjustment of baseline differences. In addition, secondary cardiovascular outcomes were largely in concordance with previous studies. The incidence of repeat revascularization was significantly higher in the PCI group, and this was a persistent finding, regardless of adjustments, similar to findings reported in previous studies (13). A similar incidence of stroke has been reported after CABG or PCI in patients with CKD (13, 14, 18), although some studies have reported a lower risk of stroke after PCI (19). In this study, we found a higher incidence of stroke after CABG than PCI.
Kidney-related events

Both PCI and CABG can cause kidney injury—PCI by contrast nephropathy (20), and CABG through renal hypoperfusion, inflammation, and decreased autoregulation (21). CKD is associated with a higher incidence of post-revascularization AKI (22, 23), but relatively few studies have compared the impacts of the two revascularization methods. 
on renal function. Although several studies have found that AKI occurs more frequently after CABG than PCI, at least in the short-term period (5, 7), there is a paucity of data on long-term outcomes. Charytan et al. analyzed patients with CKD undergoing PCI or CABG and reported that rates of end-stage kidney disease were similar between the two groups (24). Although our definition of kidney-related secondary outcome differed from that of Charytan and colleagues, we observed a significantly higher incidence of renal outcomes in the CABG group than in the PCI group. The Kaplan–Meier curve demonstrated a large proportion of kidney-related events occurred during the early post-operation phase, while a landmark analysis showed that differences in the incidence rates between the groups were more prominent before than after the 30-day time point. Our results indicate that patients with CKD are at a relatively high risk of acute kidney-related events.

TABLE 3 Cumulative incidence of events at 5 years in the CABG, PCI-CR, and PCI-IR groups.

| Variables              | CABG (N = 443) | PCI-CR (N = 132) | PCI-IR (N = 223) | P-value (CABG vs PCI-CR) | P-value (CABG vs PCI-IR) | P-value (PCI-CR vs PCI-IR) |
|------------------------|----------------|------------------|------------------|-------------------------|-------------------------|-------------------------|
| MACCE                  | 85 (19.3%)     | 22 (16.7%)       | 63 (28.3%)       | 0.60                    | 0.01                    | 0.02                    |
| Death                  | 57 (13.0%)     | 17 (12.9%)       | 54 (24.3%)       | 1.00                    | <0.001                  | 0.02                    |
| Cardiac death          | 36 (8.4%)      | 9 (7.0%)         | 33 (15.6%)       | 0.76                    | 0.01                    | 0.04                    |
| Acute myocardial infarction | 4 (1.0%)    | 2 (1.6%)         | 8 (4.0%)         | 0.91                    | 0.03                    | 0.42                    |
| Stroke                 | 37 (8.8%)      | 6 (4.6%)         | 9 (4.4%)         | 0.20                    | 0.06                    | 1.00                    |
| Repeat revascularization | 9 (2.2%)     | 10 (8.1%)        | 26 (12.9%)       | 0.04                    | <0.001                  | 0.30                    |
| Renal composite outcome* | 160 (36.6%)  | 35 (26.9%)       | 72 (33.8%)       | 0.05                    | 0.37                    | 0.31                    |

*Renal composite outcome was defined as a decrease in the GFR of more than 40%, initiation of dialysis, or kidney transplant during the follow-up.

TABLE 4 Clinical outcomes at 5 years in the CABG, PCI-CR, and PCI-IR groups.

| Variables              | Univariable analysis | Multivariable analysis* | IPW analysis |
|------------------------|----------------------|-------------------------|--------------|
|                        | HR (95% CI)          | P-value                 | HR (95% CI)  | P-value         | HR (95% CI)  | P-value         |
| CABG vs. PCI-CR (CABG as reference) |                      |                         |              |                 |              |                 |
| MACCE                  | 0.86 (0.54–1.38)     | 0.54                    | 0.88 (0.53–1.49) | 0.64       | 0.88 (0.53–1.48) | 0.63         |              |
| Death                  | 0.99 (0.57–1.69)     | 0.96                    | 0.99 (0.54–1.82) | 0.98       | 1.06 (0.58–1.92) | 0.86         |              |
| Cardiac death          | 0.83 (0.40–1.71)     | 0.61                    | 0.81 (0.36–1.82) | 0.62       | 0.86 (0.38–1.93) | 0.72         |              |
| Acute myocardial infarction | 1.66 (0.30–9.07)   | 0.55                    | 1.15 (0.16–8.01) | 0.89       | 1.41 (0.25–7.81) | 0.39         |              |
| Stroke                 | 0.54 (0.23–1.27)     | 0.16                    | 0.64 (0.25–1.66) | 0.36       | 0.53 (0.21–1.35) | 0.18         |              |
| Repeat revascularization | 3.78 (1.54–9.30)   | 0.004                   | 3.27 (1.17–9.10) | 0.02       | 3.94 (1.54–10.00) | 0.004       |              |
| Renal composite outcome† | 0.64 (0.44–0.92)   | 0.02                    | 0.60 (0.40–0.90) | 0.01       | 0.64 (0.44–0.94) | 0.02         |              |
| CABG vs. PCI-IR (CABG as reference) |                      |                         |              |                 |              |                 |
| MACCE                  | 1.54 (1.11–2.13)     | 0.009                   | 1.59 (1.12–2.27) | 0.01       | 1.68 (1.21–2.04) | 0.002       |              |
| Death                  | 1.98 (1.36–2.87)     | 0.001                   | 1.94 (1.30–2.89) | 0.000      | 2.18 (1.49–3.19) | <0.001      |              |
| Cardiac death          | 1.91 (1.19–3.07)     | 0.01                    | 1.80 (1.08–3.00) | 0.02       | 2.16 (1.34–3.49) | 0.002       |              |
| Acute myocardial infarction | 4.27 (1.28–14.17)  | 0.02                    | 6.59 (1.77–24.58) | 0.005     | 4.56 (1.35–15.40) | 0.02        |              |
| Stroke                 | 0.50 (0.24–1.03)     | 0.06                    | 0.58 (0.27–1.26) | 0.17       | 0.50 (0.24–1.04) | 0.07        |              |
| Repeat revascularization | 6.33 (2.96–13.51)  | 0.001                   | 6.97 (3.15–15.45) | <0.001    | 6.21 (2.89–13.33) | <0.001      |              |
| Renal composite outcome† | 0.80 (0.61–1.06)   | 0.13                    | 0.74 (0.55–1.00) | 0.05       | 0.90 (0.68–1.19) | 0.45        |              |
| PCI-CR vs. PCI-IR (PCI-CR as reference) |                      |                         |              |                 |              |                 |
| MACCE                  | 1.78 (1.09–2.89)     | 0.02                    | 1.71 (1.04–2.82) | 0.03       | 2.09 (1.21–3.60) | 0.008       |              |
| Death                  | 2.01 (1.17–3.47)     | 0.01                    | 1.93 (1.11–3.36) | 0.02       | 2.06 (1.13–3.77) | 0.02        |              |
| Cardiac death          | 2.32 (1.11–4.84)     | 0.03                    | 2.24 (1.06–4.74) | 0.04       | 2.50 (1.15–5.65) | 0.03        |              |
| Acute myocardial infarction | 2.49 (0.53–11.71)  | 0.25                    | 2.20 (0.84–10.92) | 0.34     | 3.15 (0.65–15.3)  | 0.16        |              |
| Stroke                 | 0.91 (0.32–2.54)     | 0.85                    | 0.78 (0.27–2.26) | 0.65       | 0.92 (0.30–2.77) | 0.88        |              |
| Repeat revascularization | 1.68 (0.81–3.49)   | 0.16                    | 1.56 (0.74–3.27) | 0.24       | 1.60 (0.75–3.43) | 0.23        |              |
| Renal composite outcome† | 1.29 (0.86–1.93)   | 0.22                    | 1.20 (0.79–1.81) | 0.39       | 1.44 (0.94–2.21) | 0.10        |              |

*Multivariable adjusted analysis was performed with the variables of age over 70 years, sex, acute myocardial infarction at presentation, hypertension, diabetes mellitus, left ventricular ejection fraction under 40%, history of stroke, left main coronary artery involvement, and three-vessel disease.

† Renal composite outcome was defined as a decrease in the GFR of more than 40%, initiation of dialysis, or kidney transplant during the follow-up.

CABG, coronary artery bypass graft; PCI-CR, percutaneous coronary intervention with complete revascularization; PCI-IR, percutaneous coronary intervention with incomplete revascularization; MACCE, major cardiac and cerebrovascular events.
during the early post-CABG period, and close attention must be paid for optimal management after surgery. Landmark analysis showed a significant difference of incidence even after the 30-day time point, indicating that patients with CKD are at a long-term risk of kidney injury after CABG. Larger prospective studies with more sensitive measurements of kidney injury are needed to clarify the underlying cause(s).

**Difference according to completeness of revascularization**

The benefits of PCI with CR compared with PCI with IR have been elucidated in various studies (8) but have not been consistently demonstrated in patients with CKD (25). We found a similar incidence of MACCE in the PCI-CR and CABG groups, while the PCI-IR group had worse outcomes. The risk of repeat revascularization was significantly lower after CABG than either type of PCI, implying that the risk of repeat revascularization stems from the characteristics of the PCI itself. PCI-CR was more protective on renal function than CABG based on Cox proportional hazard analysis, regardless of the adjustment method. Interestingly, the PCI-IR group did not have a significantly different incidence of renal composite outcomes from either the PCI-CR group or the CABG group. Due to this, it is unclear whether PCI-CR can really provide renal protection for patients with CKD compared to CABG or if this advantage is specific to our study setting. Moreover, the contrast volume used in the PCI-CR group was significantly larger than that used in the PCI-IR group, indicating a higher risk of contrast-induced nephropathy.

These findings altogether imply that PCI-CR can provide more favorable cardiovascular outcomes than PCI-IR can for coronary artery disease in CKD to a degree comparable to CABG and might also provide additional protection of kidney function. In practice, achieving CR is not always possible with PCI due to various factors, such as coronary anatomy and patients’ clinical status, so determining which method is better to achieve CR prior to treatment would be very important. In addition, it can be argued that if PCI is chosen as a revascularization method, CR must be attempted to warrant more favorable outcomes. Further studies are needed to evaluate the overall effects of complete revascularization on patients’ outcomes.

**Limitations**

Drastic differences were found in baseline characteristics between the PCI and the CABG groups. PCI was more frequently performed in high-risk patients, such as those with old age, worse left ventricular systolic function, or diabetes mellitus. By contrast, patients with left main involvement and three-vessel disease were more likely to undergo CABG than PCI. To overcome this discrepancy, we established several exclusion criteria to balance the characteristics of the study population, adjusted for multiple factors, and performed matching by IPW analysis. However, these efforts had a limited effect, evidenced by relatively high standard mean differences even after weighted adjustment. Although our analysis implies that the CABG group is at higher risk of having kidney-related events, interpretation may be limited as we could not observe a definite trend of worsening GFRs over the follow-up period. A longitudinal curve regarding the GFR for each group may have provided the clearer message, but it was unavailable due to missing data and different follow-up periods between the two groups. In addition, we did not distinguish between CR and IR in the CABG group, possibly underestimating the effect of CR by CABG. Patients on dialysis were excluded because the renal composite outcome in this study included the first initiation of dialysis, thus limiting extrapolation of our findings to patients with end-stage renal disease. Finally, the creatinine value of the patients before the acute baseline event could not be identified in several cases, making it difficult to determine the presence of AKI at presentation, and the patients with AKI were not excluded from our study.

**Conclusion**

The incidence of MACCE is similar after CABG and PCI, but kidney-related events are significantly more frequent after CABG, especially in the early post-procedure phase. Achieving CR with PCI might prevent the adverse outcome and improve the prognosis comparable to that of CABG with the possibility of more favorable outcomes in kidney function. Therefore, if PCI is chosen to treat coronary disease in patients with CKD, it is important that physicians try to achieve CR to ensure favorable outcomes regarding the patients’ cardiovascular and renal outcomes. Further large-scale studies are needed to confirm our findings.

**Data availability statement**

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

**Ethics statement**

The studies involving human participants were reviewed and approved by the Institutional Review Board of Samsung Medical Center. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
Author contributions

KC and YS contributed to the conception and design of the study. WK and KC prepared the initial manuscript and performed the statistical analysis. SL organized the database. JL, TP, JY, J-YH, S-HC, SC, YC, KS, WSK, H-CG, and YL performed the procedure and registered the initial data to the database. All authors contributed to manuscript revision, and read and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.951113/full#supplementary-material

References

1. Cai Q, Mukku VK, Ahmad M. Coronary artery disease in patients with chronic kidney disease: a clinical update. Curr Cardiol Rep. (2013) 9:331–9. doi: 10.2174/1573403X106661024122234
2. Tonelli M, Munter P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. (2012) 380:807–14. doi: 10.1016/S0140-6736(12)60572-8
3. Yong I, Tian J, Zhao X, Yang X, Xiong H, He Y, et al. Optimal treatment strategies for coronary artery disease in patients with advanced kidney disease: a meta-analysis. Ther Adv Chronic Dis. (2021) 12:20462232211024367.
4. Li X, Xiao F, Zhang S. Coronary revascularisation in patients with chronic kidney disease and end-stage renal disease: a meta-analysis. Int J Clin Pract. (2021) 75:e14506. doi: 10.1111/iscp.14506
5. Chang T, Leong TK, Boothroyd DR, Hlatky MA, Go AS. Acute kidney injury after CABG versus PCI: an observational study using 2 cohorts. J Am Coll Cardiol. (2018) 64:985–94. doi: 10.1016/j.jacc.2018.04.077
6. Coca SG, Singanamalla S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. (2012) 81:442–8.
7. Gaipov A, Molnar MZ, Potukuchi PK, Sumida K, Szabo Z, Ahlborg O, et al. Acute kidney injury following coronary revascularization procedures in patients with advanced CKD. Nephrol Dial Transplant. (2019) 34:1894–901.
8. Gaba P, Gersh BJ, Ali ZA, Moses JW, Stone GW. Complete versus incomplete coronary revascularization: definitions, assessment and outcomes. Nat Rev Cardiol. (2021) 18:155–68. doi: 10.1038/s41569-020-02457-5
9. Gossl M, Faxon DP, Bell MR, Holmes DR, Gersh BJ. Complete versus incomplete coronary revascularization: definitions, assessment and outcomes. Nat Rev Cardiol. (2021) 18:155–68. doi: 10.1038/s41569-020-02457-5
10. Takahashi K, Serruys PW, Gao C, Ono M, Wang R, Thuijs D, et al. Ten-year outcomes of patients with stable coronary disease and chronic kidney disease: 10-year follow-up of the medicine, angioplasty, or surgery study II trial. Nephrol Dial Transplant. (2020) 35:1369–76. doi: 10.1093/ndt/ggz577
11. Giustino G, Mehran R, Serruys PW, Sabik JF III, Milोjevic M, Simoncata, et al. Left main revascularization with PCI or CABG in patients with chronic kidney disease: excel trial. J Am Coll Cardiol. (2018) 72:754–65.
12. Lima EG, Charytan DM, Hube W, de Azevedo DFC, Garzillo CL, Favaratorto D, et al. Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the medicine, angioplasty, or surgery study II trial. Nephrol Dial Transplant. (2020) 35:1369–76. doi: 10.1093/ndt/ggz577
13. Lin TC, Lu TM, Huang FC, Hsu PF, Shih CC, Lin SJ, et al. Coronary artery bypass surgery versus percutaneous coronary intervention for left main coronary artery disease with chronic kidney disease. Int Heart J. (2018) 59:279–85.
14. Chen X, Zhang X, Yan Y, Wang G. The better option of revascularization in complex coronary artery disease patients complicating with chronic kidney disease: a review and meta-analysis. Curr Probl Cardiol. (2021) 46:100886. doi: 10.1016/j.cpcrd.2021.100886
15. Wu P, Luo F, Fang Z. Multivessel coronary revascularization strategies in patients with chronic kidney disease: a meta-analysis. Cardiorenal Med. (2019) 9:145–59. doi: 10.11159/000494116
16. Zhang X, Hui L, Zheng W. Percutaneous coronary intervention versus coronary artery bypass graft in acute coronary syndrome patients with renal dysfunction. Sci Rep. (2018) 8:2283. doi: 10.1038/s41598-018-20651-3
17. Lima EG, Charytan DM, Hube W, de Azevedo DFC, Garzillo CL, Favaratorto D, et al. Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the medicine, angioplasty, or surgery study II trial. Nephrol Dial Transplant. (2020) 35:1369–76. doi: 10.1093/ndt/ggz577
18. Giustino G, Mehran R, Serruys PW, Sabik JF III, Milоjevic M, Simoncata, et al. Left main revascularization with PCI or CABG in patients with chronic kidney disease: excel trial. J Am Coll Cardiol. (2018) 72:754–65.
19. Doulamis IP, Tzani A, Troumas A, Ilipoulous DC, Kampaktsis PN, Brisaoulis A. Percutaneous coronary intervention with drug eluting stents versus coronary artery bypass graft surgery in patients with advanced chronic kidney disease: a systematic review and meta-analysis. Semin Thorac Cardiovasc Surg. (2021) 33:958–69. doi: 10.1053/j.semtcvs.2020.11.005
20. Tehrani S, Laing C, Yellon DM, Hausenloy DJ. Contrast-induced acute kidney injury following PCI. Eur J Clin Invest. (2013) 43:483–90.
21. Coppolino G, Presta P, Saturno L, Fiuano G. Acute kidney injury in patients undergoing cardiac surgery. J Nephrol. (2013) 26:32–40. doi: 10.5030/jn.2000215
22. Chew STH, Hwang NC. Acute kidney injury after cardiac surgery: a narrative review of the literature. J Cardiothorac Vasc Anesth. (2019) 33:1122–38. doi: 10.1053/j.jvca.2018.08.003
23. Almedrarez M, Gurum HS, Marian J Jr., Montorfano M, Brilakis ES, Mehran R, et al. Procedural strategies to reduce the incidence of contrast-induced acute kidney injury during percutaneous coronary intervention. JACC Cardiovasc Interv. (2019) 12:1877–88. doi: 10.1016/j.jcin.2019.04.055
24. Charytan DM, Zelevinsky K, Wolf R, Normand ST. All-cause mortality and progression to end-stage kidney disease following percutaneous revascularization or surgical coronary revascularization in patients with CKD. Kidney Int Rep. (2021) 6:1580–91. doi: 10.1016/j.ekeyr.2021.03.882
25. Kim J, Lee JM, Choi KH, Bhee TM, Hwang D, Park J, et al. Differential clinical outcomes between angiographic complete versus incomplete coronary revascularization, according to the presence of chronic kidney disease in the drug-eluting stent Era. J Am Heart Assoc. (2018) 7:e007962. doi: 10.1161/JAHA.117.007962

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.